Related Experiment Video
Updated: Aug 9, 2025

10:35
Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
11.2K
Proximal interphalangeal joint prosthetic arthroplasty.
1Institut Monégasque de Médecine et Chirurgie Sportive (IM2S), 11, Avenue d'Ostende, Monaco 98000, Monaco.
Hand Surgery & Rehabilitation
|February 21, 2023
Summary
Surgical options for painful proximal interphalangeal (PIP) joints have advanced. This review details PIP joint prostheses, focusing on indications and available options for mobility and pain relief.
Area of Science:
- Hand Surgery
- Orthopedic Surgery
- Biomaterials Science
Background:
- Painful proximal interphalangeal (PIP) joint arthritis is a common condition.
- Historically, arthrodesis (fusion) was the primary surgical treatment.
- Patient demand for mobility and pain relief has driven the development of alternatives.
Purpose of the Study:
- To review the evolution of proximal interphalangeal (PIP) joint prostheses.
- To identify key indications for PIP joint prosthetic arthroplasty.
- To describe the various PIP joint prostheses currently available.
Main Methods:
- Literature review of historical and current PIP joint arthroplasty techniques.
- Analysis of prosthesis design, materials, and surgical approaches.
- Discussion of factors influencing prosthesis selection and outcomes.
Main Results:
- PIP joint arthrodesis remains a gold standard for some patients.
- Prosthetic arthroplasty offers improved mobility and pain relief.
- The development of PIP prostheses has been complex, with market fluctuations due to complications and commercial factors.
Conclusions:
- Prosthetic arthroplasty is a viable option for select patients with destroyed PIP joints.
- Careful patient selection, prosthesis choice, and surgical technique are crucial for successful outcomes.
- Understanding the history and available options is essential for surgeons managing PIP joint destruction.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
238
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238
Phosphoinositides and PIPs
8.6K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.6K

